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 Abstract 
 
Over the past decade, there has been an explosion of information related to the protein-
protein interactions within specific organisms. However, our understanding of the 
interactions between a pathogen and its host has lagged behind. This research uses 
ordinary differential equations and interaction data to model the progression of H. pylori 
infection, a major risk factor for gastric cancer. This model allows the study of proteins in 
the MAP Kinase and Apoptosis pathways and their change under bacterial stimulation. 
Microarray experiments performed on epithelial cells confirmed the time-course of the 
infection progression. These techniques were incorporated into the study of the HIV-1 
viral infection that has a larger number of interactions, a handful of major interactions in 
H. pylori versus hundreds in HIV-1 infection. Interaction information gathered from 
human sequence motifs co-opted by HIV-1 for infection formed the basis of a predictor 
for the progression of the infection. Since HIV-1 easily develops resistance to multiple 
anti-retrovirals and high viral loads lead to increased mortality and morbidity, it is 
important to pick a drug that will inhibit viral replication. A logistic regression model 
trained with these sequence motifs as predictors has a high accuracy and specificity in 
choosing the correct drug when predicting historical samples. In an effort to expand these 
historical samples, which sequence only a small fragment of the HIV-1 genome, a viral 
linkage map was developed. This linkage map, similar to the human HAPMAP project, 
describes the evolutionary linkage across the HIV-1 genome. This allows researchers to 
gather the likely mutations on unsequenced regions of the virus and is the first step in a 
whole viral genome view of HIV-1 infection. 
 
  
Chapter 1: Introduction 
Summary 
Proteins are the workhorses of virtually every biological process in eukaryotic cells. 
While each individual protein may only have a small number of functions, the complex 
interactions between the thousands of proteins produces the variability seen throughout 
life. Nature has evolved these interactions into functional pathways of interactions that 
propagate signals from outside the cell, through varying levels of integration and 
filtering, to produce a cellular response to an environmental stimulus. Proteins share 
reusable functional blocks, termed motifs, which allow for promiscuous interaction 
partners. However, pathogenic proteins also express these motifs and this facilitates the 
hijacking of normal cellular functions. Machine learning techniques allow us to predict 
these interactions and relate them to clinical outcomes. 
Protein Structure and Function 
Current estimates imply that there are more than 100,000 gene products in the human 
proteome [1]. Proteins are a sequence of amino acids bound together to form a long 
string, the primary structure [2]. Each of the twenty amino acids which can make up a 
protein have a unique side chain which defines its molecular properties [3]. The order of 
amino acids in the primary structure partially defines the resulting structure and function 
of the protein. 
Local interactions between the side chains of each amino acid cause a local folding in the 
primary structure. This folding creates a secondary structure composed of alpha-helices 
 and beta-sheets. Alpha-helices are often found near non-polar and neutral amino acids 
like Methionine, Alanine and Leucine or some polar amino acids like Glutamic acid and 
Lysine [3, 4]. Beta-sheets are formed from the hydrogen bonds found in large amino 
acids like Tyrosine, Tryptophan and Phenylalanine [3, 4]. While there are many 
applications of the alpha-helices, their rod-like structure is often found in proteins 
involved in structural functions [5] or membrane spanning domains [4]. Beta-sheets often 
comprise the docking site for enzymatic reactions [6]. 
Beyond the local interactions that form the secondary structure, the tertiary structure 
folds the entire set of beta-sheets and alpha-helices into a complex three-dimensional 
object. This structure is anchored by disulfide bridges, hydrophobic interactions and ionic 
interactions [3]. After folding, a protein can undergo any number of post-translational 
modifications including, but not limited to: cleavage [7], glycosylation [8], 
phosphorylation [9] or ubiquitination [10]. 
Determining the three-dimensional structure of a protein is a difficult task. The traditional 
molecular biology technique is to form crystals of the desired protein and use x-ray 
diffraction to view the complex structure [11-13]. However, this is a time consuming task 
that to date does not have a ―proteome-scale‘ solution [14]. Furthermore, some classes of 
proteins are highly distorted by the crystal forming process [15]. To date, only a small 
fraction of the human proteome has been crystallized in this fashion [16-20]. 
Modern computer science techniques attempt to solve these three-dimensional structures 
in-silico. Molecular Dynamics techniques use Newtonian mechanics to simulate the 
atom-scale interactions [21, 22]. Homology models attempt to map a new sequence into a 
set of known structures [23-25]. There has even been work on using people and our 
 natural problem solving skills to create a game out of protein structure prediction [26]. 
However, even the most sophisticated folding programs can only solve a tiny subset of 
the proteome [27].  
After folding, proteins interact with numerous partners. These interactions are defined by 
the three-dimensional structure of each protein [28]. Research into the interaction 
networks of several organisms have found scale-free network [29-31], this has been 
replicated in yeast [32, 33], fruit fly [34] and human [35-37]. This type of network has a 
power-law distribution in the number of connections for each node [31]. In biological 
terms, this means that there are a few proteins that interact with many partners. However, 
there are many proteins that interact with only a few partners. Proteins with many 
interaction partners are called ―hubs‖ [38]. One advantage to this strategy is that any 
random deletion or insertion is unlikely to cause a lethal phenotype. 
Hubs act as regulators of information flow within a cell. They have been shown to be 
correlated with lethal knockout mutations [39], involved in multiple cellular processes 
[40], highly conserved through evolution [41, 42] and targeted for viral hijacking [43-47]. 
Hubs and their binding partners interact through a re-usable set of binding motifs which 
only slightly differ between individual proteins [48]. 
Due to the complex nature of protein structures, it is difficult to use the three-dimensional 
structure in any analysis pipelines. Recent research has used these structures for ―rational 
drug design‖ which employs docking software to predict small molecules which may 
inhibit normal or aberrant function [49, 50]. This is opposed to the traditional screening 
method in which millions of compounds are tested with little forethought [51]. However, 
 researchers are still exploring these techniques and they have adopted them into the 
majority of research applications. 
Functional Sequence Motifs 
Motifs are a way to ‗side-step‘ the analysis of a large feature space by looking for 
conserved patterns within the features. Once these patterns have been found and 
validated, we can safely ignore the remaining data as ‗extraneous‘. Biologists have 
applied this methodology to protein-protein interaction networks [52], transcription factor 
binding sites [53], secondary structure prediction [54], enzymatic activity [55], and the 
identification of functional residues [55, 56]. All of these methods search for statistical 
over-representation of patterns within a dataset of known classifications. These patterns 
are then applied to new proteins. 
While all of these provide useful information, this thesis focuses on the identification of 
functional residues on various proteins. There are numerous tools for identifying these 
sites. Tools such as miniMotif [57-59] and PSI-BLAST [60] search for an over-
represented set of amino acids. These de novo motif algorithms require a set of proteins 
with a known function and a background set of proteins without the desired function. 
MiniMotif uses a k-mer approach and annotates all sequence segments which occur more 
often in the known dataset than the background dataset [57-60]. PSI-BLAST uses the 
common BLAST search tool to find proteins that are similar to the query set. Then it uses 
an iterative algorithm to refine a common segment within all query proteins [60]. 
However, in instances where the function is already well studied a de novo motif finder is 
not appropriate. For these the PROSITE [55, 61], Eukaryotic Linear Motifs (ELM) [56] 
 and PFAM [62, 63] databases curate a large collection of linear sequence motifs. 
PROSITE defines its motifs as regions of ~100 amino acids that conform to a specific 
Hidden Markov Model (HMM). An HMM is a transition matrix which calculates the 
likelihood that a segment of a sequence matches a known pattern of sequences [64]. The 
ELM database curates a list of smaller motifs, usually 3-10 amino acids, and defines its 
patterns as a set of regular expressions [56]. A regular expression is a computer science 
technique that facilitates extremely fast string searching. For simple motifs, this 
abstraction holds. For example the regular expression [RKY]..P..P, which 
corresponds to an SH3 recognition domain, can be read as ―Agrinine, Lysine or Tyrosine 
followed by any two amino acids followed by a Proline followed by any two amino acids 
followed by a final Proline‖ and an example of this is shown in Figure 1. These 
functional motifs have been used to predict protein-protein interactions [65], post-
translational modifications [66], and biological function [67]. 
 
Figure 1: A set of amino acids with the SH3 recognition site [RKY]..P..P marked in white text. 
In this thesis, I discuss the numerous applications of functional motifs to studying viral 
and bacterial infections. Research has shown that bacterial and viral pathogens create 
proteins which hijack the motifs expressed on human proteins [43-47]. This is explored 
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 using modeling techniques that capture the time course of H. pylori infection. This was 
published in the Journal of Theoretical Biology. This is followed by an example of using 
functional motifs on HIV-1 proteins to predict the therapeutic progression of infection; 
this work has been published in BMC Medical Genomics. The lack of whole genome 
data in HIV-1 studies has led to a study of the linkages within the HIV-1 genome and a 
method for inferring sequences outside of the observed region. This work is in the 
submission process.  
 Chapter 2: Perturbations in the signaling pathways of the host by the proteins of 
invading H. pylori proteins 
Summary 
Helicobacter pylori (H. pylori) is a gram-negative bacterium which infects the stomach 
of approximately 50% of the world population. Chronic H. pylori infection is a risk factor 
for developing chronic gastric ulcers and gastric cancer. The bacteria produce two main 
cytotoxins: Vacuolating cytotoxin A (VacA) and Cytotoxin-Associated gene A (CagA).  
These proteins interfere with the MAP Kinase and Apoptosis signaling pathways leading 
to aberrant cell growth and premature apoptosis. These quantitative models were 
integrated into a larger protein network within the CellDesigner tool. The resulting 
network of differential equations was perturbed by bacterial interactions as noted in 
published literature. The alterations in the function of this protein network due to 
interaction of bacterial proteins were simulated under increasing levels of bacterial load.  
This affects the MAP Kinase signaling in a dose dependant manner. Simulation results 
show that bacterial load can also aberrantly activate both pathways without external 
stimulation. Analysis of a public microarray dataset of H. pylori infected stomach 
epithelium was enhanced by promoter analysis of significant genes and showed 
agreement with the simulation results. This quantitative model allows us to explore the 
dose and time dependant nature of an infection. Simulations and microarray analysis 
show that H. pylori has a dual stage pathogenic behavior: first an initiation of growth 
defects and subsequent initiation of apoptosis. This insight allowed us to further interpret 
the dynamics of an infection time course and suggest further experiments to elucidate the 
bacterial affect on host responses. The technique described is shown in Figure 2. 
     
Figure 2: A diagram showing the method used for the study of H. pylori infections. Arrows indicate 
processes, rectangles indicate external sources and rounded rectangles represent derived products. 
Background 
H. pylori is a gram-negative bacterium that can inhabit the acidic conditions of the human 
stomach. It can chronically infect individuals and is estimated to inhabit approximately 
50% of the world‘s population [68]. Chronic H. pylori infection is a major risk factor for 
gastric ulcers and gastric cancer [68]. 
H. pylori effects host stomach epithelial cells by producing two unique cytotoxins: 
Vacuolating cytotoxin A (VacA) and Cytotoxin-Associated gene A (CagA) [69, 70]. 
VacA has been implicated in hyper-vacuolization, small molecule leakage and apoptosis 
[69]. CagA has been implicated in morphological changes (―hummingbird‖ phenotype) 
and induction of the MAP Kinase pathway [70]. 
VacA acts as both a trans-membrane channel and a protein activator [71, 72]. VacA 
associates with planar lipid membranes such as the outer cell membrane, vesicles and 
 mitochondrial membranes [72]. When VacA associates with vesicle membranes it creates 
a leak channel which eventually leads to vesicle swelling [69]. This hyper-vacuolization 
is a drastic phenotypic effect noticed in-vitro however rarely under in-vivo conditions 
[69]. Blocking the hyper-vacuolization phenotype has no effect on the VacA induced 
apoptosis rates [73] since the effect is independent of vesicle activity. When VacA 
associates with the mitochondrial membrane it begins to activate the BAX protein [73]. 
This protein catalyzes the release of Cytochrome C from the mitochondria which then 
begins the apoptosis cascade through the type II pathway downstream of the traditional 
activators [74]. 
CagA is injected into the host cytosol through a type IV secretory system [75]. Within the 
cytosol it can interact with the Grb-2 and SOS proteins to activate the MAP Kinase 
pathway in a Ras-dependant manner [76]. It is also phosphorylated by the host protein 
SRC kinase [77]. In the phosphorylated form, it can bind to the host protein Shp-2 and 
relieve its structural inhibition. Activated Shp-2 directly activates mapK in a Ras-
independent manner [78]. CagA also activates the host protein CSK which preferentially 
phosphorylates and de-activates SRC kinase [77]. This provides a feedback loop that 
modulates the activity of CagA. 
The H. pylori affected pathways, mainly MAP Kinase and Apoptosis, have been 
extensively studied and reviewed by others [79-81]. Quantitative models of these 
pathways have been developed using rate equations and experimentally determined 
binding constants [82, 83]. We used this work as a foundation to computationally 
simulate the interaction of H. pylori proteins with the host epithelial cell protein networks 
in order to identify the critical modes of these interactions that lead to increasing rates of 
 growth and apoptosis. We have compared our findings in a time dependant manner with 
the transcription factor activation data obtained from publicly accessible microarray data 
[84] and PAINT analysis [85]. 
Our results indicate a bacterial load dependant activation of the MAP Kinase and 
Apoptosis pathways. This dependency varies based on whether the pathway was 
stimulated by physiological conditions. The time dependant transcription activation 
predicted by the model equations agree with the outcome of the microarray data 
indicating that present mathematical formulations of MAP Kinase and Apoptosis 
pathways are able to reproduce response to bacterial challenges to the host cell. 
Methods 
Quantitative Model 
Quantitative interactions of H. pylori bacteria proteins with the host epithelial cell 
proteins are described below in a pathway specific manner. The pathways affected by 
bacterial proteins were previously shown to be the MAP Kinase and the Apoptosis 
pathways in a large number of experimental studies as reviewed in [71, 86]. Figure 3 
shows a simplified schematic of the affected pathways while Figure 4 shows the entire 
network model and its interactions. 
  
Figure 3: Block Diagram of H. pylori effects on the MAP Kinase and Apoptosis pathways. H. pylori proteins are in red, apoptosis in blue, MAP Kinase in 
green and signaling proteins are in orange. 
  
Figure 4: Entire Diagram of H. pylori effects on the MAP Kinase and Apoptosis pathways. H. pylori proteins are in red, apoptosis in blue, MAP Kinase in 
green and signaling proteins are in orange. 
 MAP Kinase Signaling Pathway 
The MAP Kinase signaling pathway equations used in our study were previously 
presented by [83]. Their mathematical model contained 120 nodes (proteins in various 
phosphorylation states) and 200 reactions between the nodes. The rate equations used in 
the model consisted of simple association reactions and Michaelis-Menten enzyme 
kinetics. We used Entrez comparison to confirm that the nodes in [83] were actually 
present in the KEGG MAP Kinase pathway [37]. Moreover, we were able to confirm the 
interaction connections between these nodes using the Ingenuity Pathway Analysis (IPA). 
The rate constants appearing in MAP Kinase pathway were previously estimated by [83]. 
The same set of constants was used in more recent analysis of the signaling pathway by 
[87, 88]. This study adopts the same rate constants and this set is presented in our 
published manuscript [89]. 
Our study involves interaction of mapK across species and hence additional constants had 
to be introduced into the analysis of the MAP Kinase pathway. Table 1 summarizes these 
equations. Previous studies have shown that the bacterial protein CagA interacts with 
GBR-2 and Shp-2 within the MAP Kinase pathway [86] and also CagA is phosphorylated 
at EPIYA motifs by the host protein SRC kinase [95]. A schematic diagram illustrating 
the interactions of bacterial CagA with the host protein network shown in Figure 4 
indicates the need of prescribing 15 rate constants describing the interactions of CagA 
with the host. The two Michaelis-Menten rate constants (k1, k2) for the enzymatic 
phosphorylation of CagA by SRC kinase were previously estimated by [90] using affinity 
purification to isolate and characterize pure SRC kinase. 
 Equation Products Reactants Modifiers Reference 
2
*1
ky
yk
dt
dy
 
1. CagA-p CagA SRC Kinase [90] 
121 *4**3 PkRRk
dt
dy
 
1. CagA—CSK 1.  CagA-pp 
2.  CSK 
 
None [78] 
6
*5
ky
yk
dt
dy
 
1.  SRC-inactive 1.  SRC-active CagA—CSK [70] 
121 *8**7 PkRRk
dt
dy
 
1.  CagA—Shp-2 1.  CagA-pp 
2.  Shp-2 
None [91-93] 
121 *8**7 PkRRk
dt
dy
 
1.  2CagA—Shp-2 1.  CagA-pp 
2.  CagA—Shp-2 
None [91-93] 
10
*9
ky
yk
dt
dy
 
1.  mapK-active 1.  mapK-inactive 2CagA—Shp-2 [94] 
121 *12**11 PkRRk
dt
dy
 
1.  GBR-2—CagA 1.  GBR-2 
2.  CagA 
None [76] 
14
*13
ky
yk
dt
dy
 
1.  BAX-active 1.  BAX-inactive VacA [72] 
Table 1: Equations added to the MAP Kinase and Apoptosis pathways 
The forward and reverse binding constants involved in the interaction between 
phosphorylated CagA and c-SRC kinase (CSK) (k3, k4) were estimated from the study 
done by [78] which used immunoprecipitation and an in-vitro kinase assay to characterize 
active CSK. Previous studies show that active CSK phosphorylates and deactivates SRC 
kinase, suggesting the presence of a feedback loop modulating the amount of active CagA 
 [70]. The rate constants for this interaction (k5, k6) were estimated based the activity of 
SRC kinase as previously mentioned. 
The next set of rate constants (k7, k8) involves the binding interaction between 
phosphorylated CagA and the host protein Shp-2 [91-93]. The constant k7 refers to the 
binding affinity between CagA and Shp-2 and k8 refers to the dissociation of the 
complex. These constants were estimated by [91, 96, 97] based on in-vitro kinetics. Shp-2 
activation produces a Ras-independent activation of mapK [94]. The next set of rate 
constants (k9, k10) describes the rate of activation of mapK by active Shp-2. In the 
absence of experimental data in the literature, these constants were assumed the same as 
those regulating the activation by activated mapKK. 
Non-phosphorylated CagA can also interact with the host GBR-2 protein [76]. This 
interaction allows GBR-2 to recruit SOS and subsequently convert the inactive GDP-Ras 
to active GTP-Ras. GTP-Ras will then continue down the MAP Kinase pathway in a Ras-
dependant nature. The parameters (k11, k12) were estimated from experiments using in 
vitro purified proteins by [76]. It is assumed that the CagA—SOS—GBR-2 complex 
activates Ras at the same rate as the SHC—SOS—GBR-2 complex [83]. 
Apoptosis Pathway 
The Apoptosis pathway of the host epithelial cell is affected by the bacterial protein VacA 
as reviewed in [69]. The Apoptosis Pathway equations used in this study were previously 
presented in [82] and again we confirmed the constituency of its nodes with the 
corresponding KEGG pathway. Moreover, an Ingenuity Pathway Analysis search also 
identified the node connections specified. Overall, this pathway has 56 nodes and 114 
reaction equations. 
 VacA reduces cell membrane integrity and increases vesicle swelling. This study assumes 
that VacA can enter the host cell cytoplasm through such a mechanism and focuses on its 
interaction with the Apoptosis pathway proteins. Specifically this model incorporates the 
VacA induced activation of the BAX protein [73, 74]. It is assumed that VacA activates 
BAX at the same rate as cellular mechanisms and that its activity is identical to 
physiologically activated BAX [82]. Estimates for the rate constants of BAX activation by 
VacA (k13, k14) were derived from experiments on isolated mitochondria and purified 
cellular proteins by [72]. 
Production of bacterial proteins was assumed to have occurred at a constant rate (k15). 
Our hypothetical bacterial cell produces CagA and VacA at constant rates that then 
diffuse across the cell membrane in a concentration dependant manner. Simulating 
varying levels of bacterial load roughly corresponds to a variable Multiplicity of Infection 
(MOI). Table 2 shows the bacterial loading and the corresponding Steady-State levels of 
the bacterial proteins. This simulation technique more closely resembles the 
transformation cell lines with conditionally active expression vectors [73, 78]. 
Numerical Simulation  
The mathematical model incorporating the interaction of invading bacterial proteins with 
the host MAP Kinase and Apoptosis pathways was constructed with the CellDesigner 
tool [98]. This program creates an SBML [99, 100] compliant model which can be 
simulated by a number of tools. The ordinary differential equations (ODEs) resulting 
from the model were solved using the MATLAB 7.0.4 ode23s function with default 
values given for ode23s [101]. The proteins in these pathways were allowed to change 
state during the transmission of the signal as defined by network equations. 
 The input and outputs of the solved pathway equations correspond to the well observed 
physiological conditions. The MAP Kinase pathway is stimulated by External Growth 
Factor (EGF) and results in an increased activation of the mapK protein that would in 
turn lead to an increase in transcription of growth factors. The Apoptosis pathway is 
stimulated by an external concentration of FasL and results in an increased concentration 
of activated Caspase-3 that would begin the destruction of cellular complexes. 
The simulations described in the next section take into account the possibility that host 
stimulation of the effected pathways modulate bacterial pathogenesis [68]. To model host 
stimulation of the respective pathways, the host cells were assumed to be exposed to a 
concentration of EGF = 0.5 uM and FasL = 0.1 uM, .resulting in subsequent stimulation 
of the MAP Kinase [83] and Apoptosis pathways [82]. 
Parameter Scan 
The parameters appearing in our simulated MAP Kinase and pathways were investigated 
previously in a parameter search space by [87, 88]. This study focuses on the impact of 
parameters (k1-k14) governing the direct interaction of host and invading proteins. For 
this reason we have multiplied by the assumed values of these 14 parameters by a 
modifying constant (Kmod) between 0.1 and 4.0. Simulations were then executed by 
altering these parameters one at a time and quantifying the time course of mapK and 
Caspase-3 activity. Note that Caspase-3 stands as a marker for apoptosis effects and 
mapK for growth. 
Microarray analysis 
Publicly accessible microarray data involving global gene expression profiles of human 
epithelial cells in the presence and absence of H. pylori infection was acquired from 
 Stanford Source Microarray Database [102]. Specifically, the data set included 
microarray data on T84 polarized monolayers taken at discrete time intervals following 
infection with wild-type H. pylori and their controls. The Stanford gene chip used in the 
microarray study consisted of cDNA spots for approximately 43,000 genes [84]. The data 
was normalized based on the standard Stanford procedure [102] into log2 normalized 
data. Table 2 summarizes the microarray data used in this study. 
 
Table 2: Summary of microarray data used for the H. pylori study along with the results of paired t-
test analysis.  
Microarray data samples from infected cells were grouped and compared to the entire 
time-course of the corresponding data for mock-infected cells (control data). This 
analysis was performed using the t-test module of the TIGR MEV tool [103-106]. Genes 
that had a p-value less than 0.01 regardless of the direction of expression change were 
saved for further analysis. The pairings used in the analysis are listed in Table 2. 
Since both the MAP Kinase and Apoptosis pathways effect transcription of functional 
genes the gene sets should have an over-representation of promoters for either apoptosis 
or growth. The PAINT promoter tool [85] is a high-throughput bioinformatics algorithm 
for promoter analysis. The PAINT analysis retrieved the 2000 bases upstream of each 
gene within the test set and searched the public TRANSFAC database [107] for known 
promoter recognition sites and their corresponding transcription factors. 
Number of Probes on the Microarray 41567
Number of Samples at Each Time-point 2
t-Test Pairings considered
T2 U T4(infected) Vs Control T4 U T8(infected) Vs Control T8 U T12(infected) Vs Control T12 U T24(infected) Vs Control
Number of Sig genes (p<0.01) 318 634 517 681
TF binding sites found 26506 18322 12431 26506
Significant TFs (p<0.1) 33 24 25 33
 Results 
In this section, we present the simulation results concerning perturbations of the 
Apoptosis and MAP Kinase pathways due to H. pylori infection using our standard rate 
constants. Next, we alter the parameters that govern the interaction of bacterial proteins 
with the host protein network one at a time to gauge the possible effects of bacterial and 
host genotypes on the predicted results. The last subsection is concerned with the 
comparison of model predictions with findings based on microarray data involving 
epithelial cells infected with H. pylori and their controls. 
Model predictions related to MAP Kinase pathway 
The bacterial protein CagA interacts at multiple points along the MAP Kinase signaling 
pathway Figure 4. It can directly activate mapK through activation of Shp-2 or activate 
RAS through interaction with GBR-2 and SOS. Consistent with the extent of interaction of 
CagA with the host protein network, our results indicate a complex set of perturbations to 
the MAP Kinase pathway as quantified in simulations by the time variant concentration 
of active mapK Figure 5. The simulations shown in Figure 5 were generated by solving 
the MAP Kinase pathway rate equations for a time-span of 32400 second (9 hours) under 
EGF stimulated (top) and non-stimulated (bottom) conditions. The figure indicates that 
the level of activation of mapK changes with bacterial load in a dose dependant manner. 
Furthermore, bacterial load shortens the time to mapK activation in a dose dependant 
manner. The time of activation of MAP Kinase pathway due to bacterial infection is 
shorter in the presence of EGF stimulation at moderate to low bacterial loads but time to 
activation decreases rapidly with increasing bacterial load as shown in Figure 6. In 
contrast, the time for de-activation is independent of the level of bacterial load.  
 The time course of MAP Kinase activation due to H. pylori infection can be better 
understood when the simulation results are plotted as a function of time for the critical 
nodes appearing within the pathway (Figure 7). The MAP Kinase nodes of the diagram 
include GBR-2—SOS—SHC complex, GTP-RAS, active Raf, RAS—Raf complex, active 
mapKK, active mapK, CagA—Shp-2 complex, inactivated GBR-2—SOS and aberrantly 
activated GBR-2—SOS—CagA. The results shown in the diagram (Figure 7) point a 
feedback loop of active mapK deactivating the GBR-2—SOS complex in modulating the 
activation length of the MAP Kinase pathway. MapK activated by bacterial proteins 
causes an aberrant feedback loop which deactivates the GBR-2—SOS complex and 
prevents the other regulatory functions of the MAP Kinase pathway from deactivating 
mapK. 
 
  
Figure 5: Activation level of the MAP Kinase cascade under varying levels of bacterial load. 
 
Figure 6: MAP Kinase activation under simulated bacterial loading and EGF stimulation. 
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Figure 7: Diagram of major nodes in the MAP Kinase pathway. Normal activation is 
in black, bacterial activation in blue and both are in red.    
 Model predictions related to Apoptosis pathway 
The bacterial protein VacA interacts with the BAX protein of the Apoptosis pathway. This 
interaction leads to a perturbation of the Apoptosis network as shown in Figure 4. The 
end result of this perturbation is exhibited in the concentration of the active form of 
Caspase-3, which is considered to be a marker for upcoming apoptosis [108]. Our results, 
obtained by solving the 114 rate equations of the apoptosis model for a time span of 
86400 seconds (24 hours), show that Caspase-3 activation is dependent on the presence 
of FasL stimulation of the host cell and the bacterial load as measured by the 
concentration of VacA in the host cell (Figure 8). FasL concentration in this 
computational simulation was held constant at 0.1uM (top) or zero (bottom) as consistent 
with standard experimental techniques [109]. Bacterial load was then varied for both 
stimulated and non-stimulated conditions. Our results indicate that FasL activation is 
Figure 8: Activation of the Apoptosis cascade under bacterial load and FasL stimulation. 
 much more efficient in a time-wise manner for inducing apoptosis compared to H. pylori 
infection (7 hours vs. >12 hours) but bacterial infection is sufficient to cause apoptosis by 
itself within the first twenty-four hours of infection. 
 
Figure 9: Activation time of the apoptosis cascade under bacterial loading 
Infection induced apoptosis is dependent on the presence FasL stimulation of the host 
epithelial cells, which might have been caused by a number of factors including 
inflammation. Figure 9 shows that FasL induced Caspase-3 activation proceeds 
independent of the level of bacterial infection whereas the bacterial infection induced 
apoptosis is highly dependent on the cellular concentration of the invading VacA protein. 
The 80% activation time shown in the figure identifies the time in which 80% of 
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 Caspase-3 had been converted to its active form. These results point to the importance of 
bacterial load in the progression of H. pylori induced gastritis. 
The model simulations presented here bring a deeper understanding of the detailed 
interrelations between various nodes within the Apoptosis pathway. Figure 10 shows the 
predicted time variant concentrations of critical nodes within the Apoptosis pathway 
under FasL stimulated and bacterial loading conditions. Each curve in a node in Figure 
10 represents the concentration of the node under bacterial load only (blue), stimulated 
only (black) and stimulated and bacterial loading (red) (bacterial cells = 0.1) conditions. 
The numerical simulation indicates two distinct modes of flow of the apoptosis inducing 
signal through the pathway. The preferred mode of flow for FasL stimulation is through 
activation of Caspase-3 directly by Caspase-8 whereas the bacterial load induced signal 
perpetuates through an alternative cycle that begins with BAX activation by VacA and 
goes through Cytochrome-C release and subsequent activation of Caspase-3. These 
results are in agreement with medical practice of eradicating H. pylori infections to 
prevent progression from gastric ulcers to cancerous regions [108].  
Activation of the Apoptosis pathway by H. pylori infection bypasses the primary mode of 
transmission through the pathway. Under bacterial loading only conditions, Caspase-8 
never activates and Interactions 2, 7, and 8 never occur since VacA perturbations activate 
the pathway downstream of Caspase-8. The VacA induced activation of BAX increases 
Cytochrome-C release through Interaction 4. This causes slower Caspase-9 activation, as 
compared to FasL stimulation, due to the interaction of XAIP that inhibits Caspase-9 
activation (not shown). Active Caspase-9 then activates Caspase-3 through Interactions 6 
 and 9. This demonstrates that bacterial induced apoptosis bypasses the primary cellular 
mode of apoptosis. 
When the simulated cell is exposed to both FasL stimulation and bacterial loading 
conditions the FasL mode of transmission dominates. As described earlier, FasL 
stimulation leads to activation of Caspase-8 and subsequent activation of Caspase-3 after 
approximately three hours. Even under high bacterial loads, the Caspase-3 activation by 
Caspase-8 preempts the hyper-activation of Caspase-9 by bacterial induced Cytochrome-
C release. This suggests a relatively simple in-vitro experiment to determine the validity 
of the model; mainly does apoptosis occur in a time dependant manner to bacterial 
loading while under constant FasL stimulation. 
Model Predictions relating to Bacterial Parameters 
Parameters that govern the interaction of bacterial proteins with the host cell proteins are 
described in Table 1. We have changed these parameters one at a time by multiplying the 
standard values with the following coefficients (0.1, 0.2, 0.5, 1, 2, 4). Results of this 
large-scale simulation show that 13 out of the 14 parameters marked in the figure could 
be varied by large amounts without significant alteration to the time course of mapK 
activation. On the other hand, the parameter k9 representing, the rate at which the 
CagA—Shp-2 complex converts inactive mapK into activated mapK (Figure 7, 
Interaction 7) strongly influenced the time to activation of mapK. Similar results are also 
valid for parameter k8, the rate constant that governs the dissociation rate of the CagA—
Shp-2 complex. These results are consistent with medical data indicating genotype 
dependence of H. pylori as a risk factor for infection induced gastritis [110]. Moreover, 
 our simulation results point to the importance of SNPs that affect the formation and 
enzymatic efficiency of Shp-2. 
 
Figure 10: Diagram of important nodes in the apoptosis cascade. FasL activation is in black, bacterial 
activation in blue and activation both are in red. 
 Microarray Analysis 
The result of signal transduction through the MAP Kinase pathway is the emergence of a 
series of transcription factors that modulate the expression of growth related genes. The 
surrogate markers for the transcription factors involved in our simulation are mapK and 
PKA. Increasing concentrations of these nodes point to increasing expression of genes 
related to the transcription factors such as AP-1 and elk-1. Similarly, the result of 
apoptosis pathway is Caspase-3 activation, which leads to a sequence of events such as 
activation of the transcription factors Oct-1 and NFkB. By using PAINT and IPA [85, 
111] tools along with publicly accessible microarray data on H. pylori infected epithelial 
cells and their controls determined the time course of the emergence of transcription 
factors that are linked to the concentration of mapK, PKA, and Caspase-3. The impetus 
for this study was to see if the time course of emergence of MAP Kinase and Apoptosis 
related transcription factors matched with the predicted time course of signal transduction 
presented in this study. 
Upon submitting the significant genes found in the analysis of the 2 and 4 hour time 
points PAINT returned a list of transcription factors that showed a statistical over-
representation these are listed in Table 3. The transcription factors that appear at this 
early stage of infection include elk-1 (p=0.00000), which is activated by mapK, and AP-1 
(p=0.00000), a transcription known to be activated by mapKK [112]. These results 
closely match with the time course of signaling of the MAP Kinase pathway predicted in 
this study (Figure 11).  
  
Figure 11: Predicted time-course of transcription factor activity from both the MAP Kinase and 
Apoptosis cascades. 
NFkB appeared as significantly over-represented (p=0.0083) in the 8 and 12 hour 
comparison. This transcription factor controls survival and inflammatory genes and is 
activated in response to apoptosis [81]. Recent studies have suggested that NFkB can be 
activated by Caspase-8 [79]. Figure 11 shows the Caspase-8 response to infection and 
stimulation. Also significantly over expressed at 12 to 24 hour time points was Oct-1 
which is known to be down-regulated by PKA activity [113] and activated in response to 
DNA damage [113]. During the early time-points, Oct-1 activity is repressed by high 
levels of PKA activity (Figure 11). However, active Caspase-3 will begin apoptotic 
events and increase DNA damage [79]. Again, these results match with the predicted 
time course of Apoptosis signaling events using the CellDesigner simulation.
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 Table 3: Results of the promoter analysis of the paired time points vs. the entire mock time-course.  The TF count referes to the number of times the conserved transcription binding site 
was observed in the retrieved sequence of the gene set.  The p-value is a significance measure comparing the measured frequency of the binding sites to the frequency of the entire database.  
Factors below the double line show no statisistical significance at that time-point however they are included for illustrative pruposes.  AP-1 is known to be controlled by mapKK activation.  
Elk-1 Is directly realated to mapK activation.  NFkB is activated by Caspase-8 activity.  Oct-1 transcriptional activity is down-regulated by PKA but up-regulated by Caspase-3 and apoptocic 
DNA damage. 
T2 and T4 T4 and T8 T8 and T12 T12 and T24
TRE\ExternalGroup TF Count p-value TRE\ExternalGroup TF Count p-value TRE\ExternalGroup TF Count All TRE\ExternalGroup TF Count p-value
AP-1/V$AP1_C 19 0 AP-1/V$AP1_C 12 0 AP-1/V$AP1_C 26 0 AP-1/V$AP1_C 38 0
AP-1/V$AP1_Q4 53 0 AP-1/V$AP1_Q2 55 0 AP-1/V$AP1_Q2 22 0 AP-1/V$AP1_Q2 54 0
AP-4/V$AP4_01 14 0 AP-1/V$AP1_Q4 109 0 AP-1/V$AP1_Q4 76 0 AP-1/V$AP1_Q4 166 0
ARP-1/V$ARP1_01 9 0 AP-4/V$AP4_01 17 0 AP-4/V$AP4_01 9 0 AREB6/V$AREB6_01 12 0
Barbie Box/V$BARBIE_01 16 0 AREB6/V$AREB6_01 7 0 Barbie Box/V$BARBIE_01 10 0 Arnt/V$ARNT_01 17 0
CCAAT box/V$CAAT_01 33 0 AhR/Arnt/V$AHRARNT_01 12 0 CCAAT box/V$CAAT_01 54 0 CCAAT box/V$CAAT_01 73 0
CDP CR3/V$CDPCR3_01 5 0 C/EBP/V$CEBP_C 9 0 CDP CR1/V$CDPCR1_01 16 0 CDP CR1/V$CDPCR1_01 99 0
CDP/V$CDP_01 6 0 CCAAT box/V$CAAT_01 93 0 CHOP-C/EBPalpha/V$CHOP_01 26 0 CDP CR3+HD/V$CDPCR3HD_01 21 0
CHOP-C/EBPalpha/V$CHOP_01 23 0 CDP CR1/V$CDPCR1_01 54 0 COMP1/V$COMP1_01 79 0 CHOP-C/EBPalpha/V$CHOP_01 36 0
COMP1/V$COMP1_01 74 0 CDP CR3+HD/V$CDPCR3HD_01 19 0 CP2/V$CP2_01 27 0 COMP1/V$COMP1_01 103 0
CRE-BP1/V$CREBP1_Q2 4 0 COMP1/V$COMP1_01 56 0 CRE-BP1/V$CREBP1_Q2 62 0 CP2/V$CP2_01 27 0
CRE-BP1/c-Jun/V$CREBP1CJUN_01 14 0 CP2/V$CP2_01 29 0 CRE-BP1/c-Jun/V$CREBP1CJUN_01 61 0 CRE-BP1/V$CREBP1_01 30 0
E2/V$E2_Q6 10 0 CRE-BP1/V$CREBP1_01 13 0 CREB/V$CREB_01 36 0 CRE-BP1/V$CREBP1_Q2 40 0
Elk-1/V$ELK1_01 29 0 CRE-BP1/V$CREBP1_Q2 42 0 E2/V$E2_Q6 10 0 CRE-BP1/c-Jun/V$CREBP1CJUN_01 91 0
Elk-1/V$ELK1_02 38 0 CRE-BP1/c-Jun/V$CREBP1CJUN_01 62 0 ER/V$ER_Q6 17 0 CREB/V$CREB_01 51 0
E47/V$E47_02 5 0.00002 CREB/V$CREB_01 57 0 Elk-1/V$ELK1_02 34 0 E2F/V$E2F_02 30 0
GATA-1/V$GATA1_06 6 0.00008 E2/V$E2_Q6 11 0 CRE-BP1/V$CREBP1_01 7 0.00005 ER/V$ER_Q6 51 0
AP-1/V$AP1_Q2 14 0.00019 ER/V$ER_Q6 17 0 E2F/V$E2F_02 11 0.00012 Elk-1/V$ELK1_01 35 0
AREB6/V$AREB6_01 5 0.0002 Elk-1/V$ELK1_01 18 0 NF-kappaB/V$NFKAPPAB_01 4 0.0083 Elk-1/V$ELK1_02 156 0
CDP CR1/V$CDPCR1_01 17 0.00034 Elk-1/V$ELK1_02 40 0 c-Myc/Max/V$MYCMAX_02 4 0.02395 Evi-1/V$EVI1_04 44 0
Brn-2/V$BRN2_01 6 0.00038 CHOP-C/EBPalpha/V$CHOP_01 10 0.00021 Elk-1/V$ELK1_01 8 0.0427 FOXD3/V$FOXD3_01 81 0
E2F/V$E2F_02 10 0.00085 E2F/V$E2F_02 11 0.00076 NF-kappaB (p50)/V$NFKAPPAB50_01 2 0.045 Gfi-1/V$GFI1_01 10 0.00002
CREB/V$CREB_01 17 0.00113 FOXJ2/V$FOXJ2_01 6 0.00925 HNF-1/V$HNF1_C 8 0.05667 AhR/Arnt/V$AHRARNT_01 5 0.00003
C/EBP/V$CEBP_C 5 0.0024 Lmo2 complex/V$LMO2COM_02 4 0.00985 PPARalpha/RXR-alpha/V$PPARA_01 1 0.05791 Oct-1/V$OCT1_07 3 0.0011
E47/V$E47_01 5 0.0027 MEF-2/V$MEF2_02 1 0.0856 ARP-1/V$ARP1_01 6 0.00258
Arnt/V$ARNT_01 7 0.00585 C/EBP/V$CEBP_C 7 0.00314
HFH-1/V$HFH1_01 5 0.00794 Cart-1/V$CART1_01 19 0.00335
Cart-1/V$CART1_01 10 0.01703 Brn-2/V$BRN2_01 6 0.01369
Evi-1/V$EVI1_04 13 0.06497 PPARalpha/RXR-alpha/V$PPARA_01 2 0.01871
USF/V$USF_Q6 12 0.08683 GATA-1/V$GATA1_05 5 0.0209
GATA-X/V$GATA_C 1 0.09891 Evi-1/V$EVI1_05 5 0.03262
PPARalpha/RXR-alpha/V$PPARA_01 1 0.09891 USF/V$USF_Q6 23 0.0515
Barbie Box/V$BARBIE_01 9 0.05182
Oct-1/V$OCT1_02 2 0.79456 Oct-1/V$OCT1_05 1 0.34698 Oct-1/V$OCT1_Q6 4 1 Oct-1/V$OCT1_02 3 0.94415
Oct-1/V$OCT1_Q6 12 1 Oct-1/V$OCT1_Q6 5 1 NF-kappaB/V$NFKB_Q6 2 0.44739 Oct-1/V$OCT1_05 0 1
NF-kappaB (p50)/V$NFKAPPAB50_01 0 1 NF-kappaB (p50)/V$NFKAPPAB50_01 1 0.34698 NF-kappaB (p65)/V$NFKAPPAB65_01 1 0.33173 Oct-1/V$OCT1_06 2 0.96713
NF-kappaB (p65)/V$NFKAPPAB65_01 1 0.54263 NF-kappaB (p65)/V$NFKAPPAB65_01 0 1 Oct-1/V$OCT1_Q6 32 1
NF-kappaB/V$NFKAPPAB_01 0 1 NF-kappaB/V$NFKAPPAB_01 0 1 NF-kappaB (p50)/V$NFKAPPAB50_01 1 0.66779
NF-kappaB/V$NFKB_C 1 0.20895 NF-kappaB/V$NFKB_Q6 0 1 NF-kappaB (p65)/V$NFKAPPAB65_01 0 1
NF-kappaB/V$NFKB_Q6 1 0.92311 NF-kappaB/V$NFKAPPAB_01 2 0.82777
NF-kappaB/V$NFKB_Q6 2 0.96908
 Conclusion 
This study integrates detailed analysis of signaling pathways related to H. pylori infection 
of epithelial cells with global gene expression patterns associated with infection and the 
time course of emergence of transcription factors modulating the growth and death of 
infected epithelial cells. The signaling pathway models used in this study are composed 
of sets of ODEs with time as an independent variable and concentrations of proteins 
appearing in these signaling pathways as dependant variables. These equations and the 
estimates of rate parameters associated with them were previously published by [82, 83]. 
We have incorporated a set of new rate equations and associated rate constants to these 
equations in order to describe quantitatively the binding interactions of H. pylori proteins 
with the protein network of human epithelial cells. One of the most important findings of 
our study is the fact that existing mathematical models of MAP Kinase and Apoptosis 
pathways stood the challenge of comparison with experiment data on perturbation due to 
bacterial infection. These findings are significant also because these signaling pathways 
investigated in this study are implicated in the transformation of human cells to a cancer 
phenotype. 
Our study showed the importance of the feedback loop in MAP Kinase mediated 
signaling as a modulator of bacterial activation of the pathway. Our simulations show that 
bacterial load activates the MAP Kinase pathway and subsequently a feedback loop of 
mapK deactivating the RAS—RAF complex modulates aberrant mapK signaling. The two 
constants that showed significant effect on the tie course of simulated infection are linked 
to binding of Shp-2 to CagA and the Shp-2 mis-activation of mapK. These proteins might 
be the loci of SNPs that modulate host response and the time course of infection. On the 
 bacterial side CagA SNPs have already been shown to have drastic effects on the host 
response [95, 114, 115]. 
The transcription factors that emerge due to the MAP Kinase signaling perturbations by 
bacterial infection lead to an increased transcription of Apoptosis inhibitors XAIP and 
FLIP [116, 117]. In addition, the bacterial protein VacA specifically binds and activates 
BAX, a protein that appears in the FasL stimulated Apoptosis pathway. Our simulations 
concerning the time course of Apoptosis signaling are consistent with the previously 
mentioned microarray data on H. pylori infected epithelial cells and their controls. Our 
simulations indicated that SNPs in the BAX protein are likely to affect the interactions the 
VacA protein and therefore the time course of infection. Genotyping of patients with H. 
pylori infection are only beginning. The use of recently developed high-throughput 
genotyping tools will lead to testing and validating the findings of this study concerning 
the SNPs in the human BAX, Shp-2 and mapK proteins. 
 Chapter 3: Host sequence motifs shared by HIV predict response to 
antiretroviral therapy 
Summary 
The HIV viral genome mutates at a high rate and poses a significant long-term health risk 
even in the presence of combination antiretroviral therapy. Current methods for 
predicting a patient‘s response to therapy rely on site-directed mutagenesis experiments 
and in vitro resistance assays. An alignment of thousands of HIV-1 sequences attested to 
extensive variation in nucleotide sequence but also showed conservation of eukaryotic 
short linear motifs on the protein coding regions. The reduction in viral load of patients in 
the Stanford HIV Drug Resistance Database exhibited a bimodal distribution after 24 
weeks of antiretroviral therapy, with a 2000 copies/ml cutoff. Similarly, patients allocated 
into responder/non-responder categories based on consistent viral load reduction during a 
24-week period showed clear separation. In both cases of phenotype identification, a set 
of features composed of short linear motifs in the reverse transcriptase region of the HIV 
sequence accurately predicted a patient's response to therapy. This method is shown in 
Figure 12. Motifs that overlap resistance sites were highly predictive of responder 
identification in single drug regimens but these features lost importance in defining 
responders in multi drug therapies. HIV sequence mutates in a way that preserves peptide 
sequence motifs that are also found in the human proteome. The presence and absence of 
such motifs at specific regions of the HIV sequence is are highly predictive of response to 
therapy. Some of these predictive motifs overlap with known HIV-1 resistance sites. 
These motifs are well established in bioinformatics databases and do not require 
identification via in-vitro mutation experiments. 
  
Figure 12: A diagram describing the method used to predict the therapeutic outcome of patients in 
the Stanford HIV-1 database. Arrows indicate processes, rectangles indicate external sources and 
rounded rectangles represent derived products. 
Background 
The Human Immunodeficiency Virus (HIV) is a single stranded RNA virus that contains 
nine genes coding for fifteen proteins [118, 119]. HIV has a powerful effect on the 
human immune system due to its ability to hijack hundreds of human proteins in a 
continued infection [120]. HIV's Pol gene codes for three important enzymes that are 
essential to the life cycle of the virus: the protein reverse transcriptase (RT) is common to 
all retroviruses and transcribes the viral RNA into double stranded DNA [119]. The RT 
enzyme has no proofreading ability [121], and hence the high mutation rate observed 
with in-vitro experiments for the HIV virus [122]. Pol also encodes the integrase protein 
which fuses the viral DNA produced by RT into the host genome [121]. The third enzyme 
coded by Pol, protease (PR), is an enzyme that cleaves the multiple proteins coded by 
 HIV's Gag and Pol genes into separate functional units [119]. Mutations at the active 
sites of these three enzymes or inhibition of enzyme activity by drugs disrupt HIV‘s 
ability to replicate in host cells and block the infection cycle [123]. 
Most of the drugs that are currently in use in controlling HIV infection target the three 
viral enzymes coded by the HIV Pol gene. Antiretroviral drugs such as zidovudine  
(AZT) , lamivudine (3TC), emtricitabine (FTC), zalcitabine (ddC), stavudine (D4T), 
didanosine (DDI) and nevirapine (NVP) target RT [124] whereas antiretroviral drugs 
such as indinavir (IDV), nelfinavir (NFV), and atazanavir (ATV) were designed as PR 
inhibitors [125]. Clinicians also use a set of entry and integrase inhibitors in HIV 
treatment [126-128]. When antiretroviral drug are used one at a time, eventually a drug 
resistant viral phenotype will emerge [129]. Viral loads (VL) from in-vitro cultures of 
HIV infected immune cells have diminishing growth rates in the presence of 
antiretroviral therapy but eventually a resistant viral phenotype emerges [130]. The 
resistance conferring mutations in the viral genome have been extensively documented 
and these mutations have been correlated to response to therapy [131-134]. Combination 
of antiretroviral drugs has the advantage of targeting multiple stages of the viral life 
cycle. The multi-target Highly Active Antiretroviral therapies (HAART) exert a high 
level of evolutionary pressure on the virus by effectively requiring multiple simultaneous 
mutations to produce resistant strains [135-137]. As a result, the virus takes much longer 
time to develop resistance to several drugs at the same time [138].  
HAART therapies often reduce viral replication to undetectable levels, decrease 
morbidity and mortality rates but nonetheless they can be ineffective in some individuals 
[139, 140]. Search for new antiretroviral drugs with different target sites along the HIV 
 sequence is ongoing. Targeting the virus itself may not be enough, however, to block the 
progress of infection. One may also have to consider the set of host proteins playing a 
crucial role in viral replication as targets for therapy. Recently, researchers have 
identified sets of human proteins that interact with HIV proteins [141] and another set of 
host proteins required for HIV infection through a functional genomics screen [142], but 
the modes of interaction of these host proteins with specific HIV proteins are yet to be 
fully explored. Nevertheless, the ability of HIV-1 viral proteins to bind within the host 
cell network is likely to play a critical role in disease progression [141]. It is possible that 
this new focus on host proteins interacting with HIV will lead to new therapies targeting 
host cells required for HIV infection [142]. 
In this study, we set out to cluster viral load response to antiretroviral therapy into 
responders and non-responders categories in multiple ways. We then used stepwise 
logistic regression to differentiate responders and non-responders using linear sequence 
motifs common to host and viral genomes as features. We focused on viral load in the 
responder/non-responder classification because recent studies indicate that CD4 cell 
count monitoring does not accurately identify individuals with virologic failure among 
patients taking antiviral therapy [143]. A novel aspect of our study is the recognition of 
bimodality [144] in the viral load reduction in antiretroviral therapy in patient data stored 
in the Stanford HIV Drug Resistance Database [145] both at eight weeks and twenty-four 
weeks after the beginning of the therapy. In total, we used three different methods for 
assigning phenotype based on viral load. Multiple modes of phenotype classification 
allowed us to identify the role of phenotype selection in determining significant features 
associated with drug response.  
 We sought out to identify linear motifs on HIV sequence that are also found in the host 
and are functionally annotated: host transcription factor binding sequence motifs [107], 
miRNA binding sequence motifs on the nucleotide sequence [146] and eukaryotic linear 
motifs [147] on the protein amino acid sequences. The motivation to use such features in 
predicting responder/non-responder categories comes from the observed phenomena of 
the virus hijacking host cell apparatus for its self replication [148]. Another important 
motivation is to develop a feature set based on viral sequence only, without requiring a 
priori information obtained via in-vitro cell assays on the identification of resistance 
sites. This type of a feature set is potentially quite attractive in exploring drug response of 
viruses to antiviral therapy in the absence of extensive data on resistance mutations. 
Previous research on quantitative prediction of patient response to antiretroviral drugs in 
HIV infection [149, 150] has employed similar and even more advanced machine 
learning algorithms than used here but focused mainly on mutations of the HIV genome 
along with clinical data. 
Methods 
Data sources 
This study utilizes sequence and clinical data from two distinct sources. All whole 
genome HIV-1 sequences were downloaded from the Los Alamos HIV Sequence 
Database [118, 151] in order to get a motif expression map of the whole genome. As of 
9/1/2006, this dataset consisted of 1112 subtype B and 922 subtype C whole genome 
sequences along with a lesser amount of samples from other subtypes. This dataset also 
contained five reference sequences for each subtype.  
 We used data from the Stanford HIV Drug Resistance Database [145] in order to 
investigate the clinical relevance of host protein and DNA motifs on the RT region of the 
HIV-1 sequence. The Stanford database curates clinical information from drug trials on 
large HIV cohorts and associates them with the sequence coding the protein targeted by 
the drug. As of 11/15/2008, the database contained few PR region sequences. However, 
the dataset contained 2019 RT sequences annotated with clinical parameters such as CD4 
counts, VLs and the specific antiretroviral therapy as shown in Table 4. Each patient in 
this subset had at least 1 sequence fragment from RT, and had 4 or more CD4 and VL 
measurements at 0, 2, 4, 8, 12, and 24 weeks during the course of constant therapy 
regimen.  
Phenotype Classification 
We focused on VL in the responder/non-responder classification [143] and examined the 
patient population using three methods of responder/non-responder classification: 
Standard Datenum (SD), Incremental Reduction (IR) and BiModal Classification (BM). 
The Standard Datenum method labels patients as responders if their VL decreases by 
100-fold over eight weeks of therapy [150]. The reduction in VL over the twenty-four 
week period logged by the Stanford HIV Drug Resistance Database exhibited a bimodal 
distribution for the patient population. Parameters of this distribution were obtained using 
the expectance maximization method described in [144] and indicated that a reduction of 
2000 copies/mL in viral load would accurately split the responder and non-responder 
distributions; we refer to this method as bimodal classification. The third method we used 
was designed to avoid potential noise issues that could arise by relying on a single 
clinical visit‘s measurement [152]. The phenotype classification according to incremental 
 reduction of the VL is such that if a patient‘s VL decreases between at least four visits 
then those patients are labeled as responders. 
  
Table 4: The therapy and responder statistics on the patients in the Stanford HIV-1 patient database. 
Responders are marked as R and Non-Responders as NR. Mean AUC refers to the average Area 
Under the Curve over 500 iterations. 
 
Linear Motifs on HIV Genome and Proteome and Resistance Site 
Our classification method uses the presence and absence of short linear motifs on the 
HIV genome. These motifs can be grouped into three basic types: eukaryotic linear 
motifs (ELMs), nucleotide based motifs and a priori based resistance mutations. In order 
to evaluate the relative positions of nucleotide motifs and protein motifs on the same 
platform, we annotated the protein motifs back to their corresponding nucleotide 
 positions. This could create some ambiguity since HIV has multiple overlapping reading 
frames. However, our clinical dataset only contained sequences from the RT region. We 
used a local BLASTx query [153] on a database of HIV-1 subtype B and C reference 
samples to translate the nucleotide fragments into their corresponding protein sequences. 
This ensured the proper translation even if the start and stop codons were missing from 
the sequence. 
The first feature group consisted of ELM ligation sites and subcellular targeting 
sequences. These were identified on HIV-1 protein amino acid sequences using the ELM 
webserver tool [147]. The webserver tool filters out ELMs that fall into the globular 
regions of proteins due to their predicted location within the 3D structure of the protein 
[147]. The second group consisted of HIV-1 sequence motifs that corresponded to 
annotated human transcription factor (TF) binding site motifs and miRNA binding sites. 
We used the MATCH ™ web server [154] to annotate the TF binding sites on HIV-1 
sequences with the public version of the TRANSFAC ® database as of 11/14/08 [107]. 
We required a core similarity of 0.75 and a global similarity of 0.70 in parameter 
assignment and chose among alternatives the method that minimized false negatives 
[154]. For the annotation of miRNA binding sites, recognition sequences for human 
miRNA were obtained from a human miRNA database [146]. As of 11/14/08, this 
database contained 417 experimentally verified human miRNA binding recognition 
sequences. The HIV sequences were scanned using the RNAhybrid program [155] and 
the background parameters of the extreme value distribution were created from 1000 
random sequences with dinucleotide distributions identical to our compiled HIV-1 
sequence database [155]. Any binding site that had a p < 0.01 was annotated as a 
 potential miRNA binding site. The third group of features consisted of resistance 
mutation sites on HIV sequence [156]. In order to capture the known HIV-1 therapy 
resistance mutation sites on the amino acid sequence of RT, we created regular 
expressions similar to ELMs which identify the known resistance conferring mutations 
(RSs) from the Stanford HIV-1 Resistance Database [145]. 
Predicting Therapy Outcome 
We used stepwise logistic regression (SWLR) to assess the potential of the extracted 
short linear sequence features along the RT sequence in differentiating between 
responders and non responders [157]. SWLR was implemented in the MATLAB™ 
2007b Statistics toolbox [101]. This regression method employs an iterative algorithm to 
determining the features that should be included in a predictive model. We used p-
value<0.01 as an entrance cutoff and p-value>0.1 as a removal cutoff. In our study, the 
algorithm converged to a final solution within 50-200 iterations.  
SWLR algorithm was applied to differentiate responders from non-responders in three 
different assignments of the phenotype for 500 iterations of 2-fold cross validation. Since 
the efficiency of the SWLR algorithm is sensitive to the class composition of the training 
data [157] we ensured that each training set consisted of roughly 50% responders and 
50% non-responders. After each set of training, we determined the specificity and 
sensitivity of our classifier on the independent testing dataset and plotted receiver 
operator characteristic (ROC) curves for each of the iterations in our scheme. The area 
under the ROC curve (AUC) represents the likelihood that one can identify a responder 
accurately using the method. This procedure was performed independently for each 
therapy regime under consideration and for the whole population shown in Table 4. 
 Results 
Responder/Non-responder classification 
Clinical annotation of more than 2000 RT sequence samples in the Stanford HIV Drug 
Resistance database contained measurements of VL at six time points during the course 
of twenty-four week therapy. The drugs used in various single and combination therapies 
as well as the numbers of HIV-1 individuals taking the therapy are shown in Table 4. As 
described in the methods section, the first classification method for responders and non-
responders, SD or Standard Datenum [150], was based on the fold-change of the entire 
patient database between the 0 and 8 week time points. The SD method classifies patients 
as responders if their viral load decreases by 100-fold over this period. All other patients 
are labeled as non-responders. As shown in Figure 13(top), this led to binomial 
distribution with clear peak identified for responders and non-responders. The second 
method for phenotype classification, Incremental Reduction (IR), is based on patients 
having steady reduction of viral load in four out of six weeks. Figure 13(middle) shows 
for this classification, the sub populations of responders and non-responders as a function 
of VL at three different instances in the clinical trial. It is clear from the figure that 
responders move towards zero VL whereas non-responders are much less mobile in this 
setting. The third method for phenotype classification (BM) was based on the observation 
that viral load reduction after 24 weeks of therapy exhibited bimodal distribution (Figure 
13 bottom). The method provided a cutoff of 2000 copies/mL to differentiate between 
responders and non-responders. Subpopulations corresponding to each drug regimen 
shown in Table 4 also exhibited similar bimodal distributions. 
 The overlap between these three methods is shown in the Venn diagram in Figure 14. 
More than half of the responders from each method are also declared responders by the 
other two methods. However, 244 of 925 patients labeled as responders by the SD 
method at 8 weeks are not considered responders after 24 weeks by the BM. This 
suggests that after a strong initial response to therapy, some patients regress between 8
th
 
and 24
th
 week of intervention with antiretroviral drugs. We used these three clinically 
relevant phenotype classification methods in order to identify sequence motifs associated 
with the responder group in each classification. 
 
Figure 13: The three classification schemes used in this manuscript.  Responders are marked in pink 
and non-responders are in blue.  The top panel represents the Standard Datenum. The middle panel 
shows the Incremental Reduction. The bottom panel shows the BiModal classification method. 
      
Figure 14: A Venn diagram showing the overlap between the Standard Datenum, Incremental 
Reduction and BiModal classification methods. 
Conserved linear motifs along HIV and their correlation with response to 
antiretroviral drugs 
Our results show that the HIV sequence, although highly variant in nucleotide sequence, 
express eukaryotic linear motifs (ELMs) that are largely conserved over hundreds of 
subtype B and subtype C sequences as shown in Figure 15. The motifs recognized in 
globular domain regions are not shown as they are less likely to be instrumental in the 
interactions of HIV-1 proteins with host targets [158]. The figure illustrates the presence 
of ELMs at high density along the flexible, domain-free regions of the HIV proteins. 
ELMs found on HIV proteins are largely conserved in frequency of appearance in 
eukaryotic proteomes (unpublished observations) and as such, these motifs are good 
candidates in feature selection for predicting response to antiviral drugs. 
  
Figure 15: Annotation of short linear motifs (Eukaryotic Linear Motifs, miRNAs binding sites, 
human transcription factor binding sites) along the viral sequence for 100 subtype C and 500 subtype 
B sequences.  The color code is as follows: homology Islands (green), human miRNA binding-sites 
(blue), human TF sites (silver), cleavage ELMs (red), ligation ELMs (purple), modification ELMs 
(brown), and export ELMs (pink).  The clinically annotated sequence region is shown in the black 
box. 
We used SWLR in 500 iterations of training and testing at equal proportions for all 
responder/non-responder samples shown in Table 4. The resulting Receiver Operator 
Characteristics (ROC) curves for IR classification for the therapy regimens presented in 
Table 4 are shown in Figure 16. These ROC curves point to high prediction accuracy of 
responders with the features used in the model. The area under the ROC curve (AUC) is 
an indicator of the trade off required between sensitivity (ability to detect true positives) 
 and specificity (ability to detect true negatives). As shown in Figure 16, random mixing 
of the responder and non-responder populations by 20% drastically reduced AUC for all 
drug regimens. Random mixing by 50% resulted in AUC values nearly equal to 0.5 as 
would be expected for randomly selected populations. These results indicate the ability of 
the features used in predicting responder/non-responder identity in logistic regression.  
The AUC values for all three phenotype classification methods are shown in Table 4. 
Note that AUC values for BM and IR phenotype classifications are similar and point to 
high accuracy of prediction of outcome with these classification methods. SD method, on 
the other hand, resulted in AUC values that were somehow smaller than the other two 
methods. It is possible that the feature set used in our analysis is not optimal for 
predicting responders after eight weeks of therapy.  
Regression Coefficients 
The number of average regression coefficients (features) found significant over 500 
training/testing iterations ranged from five to ten features depending on the drug 
regimens presented in Table 4. These features consisted of two specific resistance sites 
(RS)s and ELMs. In a set of control SWLR computations, we used other motifs such as 
human transcription binding site motifs and miRNA binding motifs on the RT sequence 
but none of them showed up as significant in regression. Shown in Figure 17 are 
regression coefficients with absolute values greater than 0.5 for the three phenotype 
classifications: SD (Figure 17), BM (Figure 18), and IR (Figure 19). Note that the two 
resistance sites on the figure are highly predictive of outcome in single drug regimens 
such as AZT and DDI targeting RT along with the ELMs that overlap this part of the 
sequence. Mutation RS V108 is a strong indicator of poor response to AZT, DDI, 3TC, 
 and AZT, 3TC combination at 8 weeks (SD classification) whereas RS M36 has negative 
effect on a larger spectrum of drug combinations (Figure 17). These two resistance sites 
are the only ones that emerged in the set of features most correlated with response to 
antiretroviral drugs. However, the regression does not lose accuracy when resistance sites 
are excluded from the features used in the analysis (data not shown). In this restricted set, 
the significance of ELMs overlapping the resistance sites increases to compensate for the 
deletion confirming the important role this sequence region plays in signaling resistance 
to some of the antiretrovirals targeting RT. Our findings point to resistance sites (or 
overlapping ELMs) having strong correlation to response to single antiretroviral therapies 
but response to HAART therapies are correlated strongly with functional host protein 
motifs that are also expressed by the RT. 
 
  
Figure 16: Receiver Operator Characteristic (ROC) curves determined by the stepwise-logistic 
regression (SWLR) for the therapy regimens presented in Table 4 using the IR classification.  The 
BOLD blue shows the average ROC curve over 500 iterations.  The solid black line indicates the 
prediction ability with 20% shuffling of the responder vs. non-responder categories.  The dashed line 
indicates the corresponding averages of completely shuffled responder vs. non-responder categories. 
  
Figure 17: A heatmap indicating the average of the SWLR regression coefficient for the motifs used in classifying the responders identified by the 
Standard Datenum method. Blue color in the ruler bar indicates that presence of an ELM motif creates greater likelihood of being in the responder 
category (R ELM) whereas red indicates greater likelihood of being in the non-responder category (NR ELM). 
  
Figure 18: A heatmap indicating the average of the SWLR regression coefficient for the motifs used in classifying the responders identified by the 
BiModal method. Blue color in the ruler bar indicates that presence of an ELM motif creates greater likelihood of being in the responder category (R 
ELM) whereas red indicates greater likelihood of being in the non-responder category (NR ELM). 
  
Figure 19: A heatmap indicating the average of the SWLR regression coefficient for the motifs used in classifying the responders identified by the 
Incremental Reduction method. Blue color in the ruler bar indicates that presence of an ELM motif creates greater likelihood of being in the responder 
category (R ELM) whereas red indicates greater likelihood of being in the non-responder category (NR ELM). 
 One of the most consistent predictors of positive outcome in most therapy regimens is the 
presence of ELM-Lig-SH3-3 (Figure 17). This is the motif recognized by SH3 domains 
of host proteins with a non-canonical class II recognition capacity [159]. The SH3 
domain is a protein–protein interaction module commonly found in intracellular signaling 
and adaptor proteins. The SH3 domains of multiple endocytic proteins have been recently 
implicated in binding ubiquitin, which serves as a signal for diverse cellular processes 
including protein destruction [159].  
The two resistance sites and the overlapping ELMs continue to be predictors of negative 
outcome in terms of response to subsets of antiretroviral therapies in phenotype 
classification based on incremental reduction of the VL (Figure 19, IR Classification). In 
this case, the consistent positive predictor is the motif ELM-Lig-MAPK-1. MAPK 
interacting molecules carry this docking motif that helps to regulate specific interaction in 
the MAP Kinase pathway [160, 161]. It is feasible that human mapk is recognizing the 
ELM on these RT proteins decreasing their efficacy through phosphorylation or other 
inhibition methods. 
Figure 18, showing the BM classification method has the resistance site M36 as a 
consistent indicator for negative response and ELM-Lig-SH2-STAT-5 as a strong 
indicator for positive response to antiretroviral therapy. This ELM is a motif recognized 
by proteins that have a significant impact on innate immunity during sepsis [162]. The 
innate immune system provides immediate defense against infection and serves as the 
first line of host defense during infection [163]. Recent research point out to the depletion 
of white blood cells associated with innate immunity and their recovery under HAART 
[164].  
 Discussion 
The deadly course of HIV infection eventually leading to AIDS and associated 
opportunistic infections have been altered thanks to combination antiretroviral therapies 
for a majority of individuals under HAART therapies. In addition, these therapies have 
reduced viral load dramatically in most patients, rendering them much less effective in 
transmitting the virus to others [165]. Recent research has focused on discovering new 
drugs targeting HIV proteins as well as identifying host proteins necessary for viral 
growth also as targets for drugs. However, the interaction between the viral and host 
genotypes jointly affecting an individual‘s response to antiretroviral drugs has not been 
fully explored. 
In this study, we hypothesized that those host sequence motifs that are involved in 
protein-protein and protein/DNA/RNA interactions and found in viral genomes are 
features that could play important roles in determining response to different combinations 
of antiretroviral drugs. The rationale behind our thinking is the accumulating 
experimental evidence that viruses utilize motifs found in host genome and protein for 
integrating into host cell molecular networks and hijacking their function for viral 
replication [166, 167]. Using linear sequence motifs shared by both the host and the virus 
provides a methodology for investigating the plausible mechanisms of host virus 
interactions that determine response to antiretroviral drugs. 
We have used known resistance sites and host motifs found on HIV reverse transcriptase 
as a feature set in differentiating responders from non-responders (weak responders) in 
stepwise logistic regression for 16 different combinations of antiretroviral drug regimens 
containing at least one drug against HIV reverse transcriptase. Responder phenotype was 
 defined by multiple ways to gain insights into drug response at 8 weeks (SD phenotype 
classification) and 24 weeks (BM phenotype classification) after the beginning of the 
therapy and somewhere in between (IR Phenotype classification). Host motifs that appear 
to be highly relevant to viral replication such as the transcription site binding motifs [168, 
169] and miRNA binding site sequence motifs [170, 171] turned out to be non-
discriminatory in determining clinical outcome. Two resistance sites on HIV RT were 
indicators of negative outcome especially for regimens consisting of antiretrovirals 
targeting RT but their influence to distinguish the outcome diminished in HAART 
therapies. These two resistance sites overlapped ELMs and they could be deleted from 
the list of features without losing prediction accuracy. On the other hand, a number of 
ELMs appeared as strongly correlated with positive outcome at different stages of 
antiretroviral therapy. These ELMs were associated with binding events leading to 
phosphorylation, ubiquination and the innate immune response. 
Our approach to relate HIV sequence motifs to the course of infection does not require a 
priori information about how HIV sequence would mutate in the presence of 
antiretroviral drugs. We were able to make accurate predictions without the resistance 
site information available in the literature. The input to our machine-learning algorithm is 
simple: the HIV sequence. We use publicly available bioinformatics tools to annotate 
these sequences with host motifs relevant to the outcome. We then identify the motifs on 
the sequence that differentiate between responders and non-responders. These motifs can 
then be linked to specific viral host protein interactions and the pathways of these 
interactions. The promise of our approach will be fully explored with the availability of 
 clinically annotated HIV whole genome sequences obtained at different time points 
during HAART therapy.  
Conclusions 
Linear binding motifs found in both the host and viral proteomes constitute a set of 
features highly predictive of response to therapy involving different combinations of 
antiretroviral drugs. Stepwise logistic regression adopted here utilizes only the HIV-1 
sequence and does not need data on resistance sites specific to various antiretroviral 
drugs. This study emphasizes finding sequence motifs which facilitate binding between 
viral and host proteins. This binding may allow the hijacking of host protein binding sites 
from their usual binding partners and thus alter the signaling pathways of the host cell. 
Our study points to competitive binding of HIV proteins to host proteins using motifs 
found in the host as the mechanism of interplay between the host and pathogen genotypes 
in dictating response to therapy. Our method is applicable to other viral infections where 
the viral sequence is known but resistance sites to antiviral therapies have not yet been 
documented.  
 Chapter 4: Decoding mutation linkages in HIV Proteome 
Summary 
HIV-1 is a persistent infection that affects a large portion of the world‘s population and is 
a major health concern in the coming decades. Recent research has focused on the 
discovery of viral mutations that confer resistance to anti-viral therapy. These studies use 
directed techniques to examine specific regions of the viral genome but ignore others.  
We have developed a viral linkage map similar to the human HapMap, using the method 
described in Figure 20, which describes the linkage between any two regions of the viral 
genome and use this linkage to predict the functional motifs of the less frequently 
sequenced regions. We find that HIV Env is the most frequently linked HIV protein to 
other proteins of the HIV proteome. Our study sheds light on the linkage properties of 
HIV sequences previously annotated for function in viral replication. The proteome 
linkage study presented here will facilitate whole-genome analysis of HIV-1 phenotypes 
and their correlation to drug resistance and immune system response. 
  
Figure 20: A schematic diagram of the technique used to create the HIV-1 sequence linkage map. 
Arrows indicate processes, rectangles indicate external sources and rounded rectangles represent 
derived products. 
Background 
HIV infects millions of people worldwide and causes a significant decrease in life 
expectancy [172]. Recent research has focused on the development of novel therapeutics 
[173, 174], optimizing current therapy [175-178], vaccine development [179-185] and 
modes of transmission [186-190]. These studies often focus their research on the Pol or 
Env since they are primarily responsible for HIV-1 reproduction [191] and encapsulation 
[191, 192] respectively. However, there has been a lack of research into the linkage 
between the entire HIV-1 proteome on a large scale. 
The proliferation of new sequencing centers and the ever-decreasing cost of Sanger and 
Next-Generation sequencing techniques increased the availability of HIV-1 sequences. 
Previous research on HIV mutations rates has been limited to a small set of HIV-1 of 
proteins. Chen et al used a database of more than 40,000 protein segments to find the 
mutation rate and amount of positive selection in the RT and PR segments [193]. These 
 proteins are often studied due to their clinical relevance and the availability of anti-
retroviral drugs [174, 194]. Computational biologists use these estimations of mutation 
rates to create simulation studies to find the likelihood of a patient gaining a resistance 
mutation [193, 195-198]. 
Current research areas also focus on the evolution of the virus within a single patient, 
dubbed the quasispecies. Rozera et al used high throughput pyrosequencing to follow 
five chronically infected HIV-1 patients during a structured therapy interruption and 
determined the mutation rate of the V3 loop of Env [199]. Tsibris et al used high 
throughput sequencing to follow the same region of the Env in four chronically infected 
HIV-1 patients and determined that minority variants can gain an increased prevalence 
after therapeutic intervention [200]. Similar deep sequencing studies have been done on 
the HIV-1 IN [201], RT [202], and Nef [203]. 
The HapMap project catalogues the linkage disequilibrium in human patients by 
systematically sequencing the genome of ancestrally related cohorts [204]. Genome-Wide 
Association Studies (GWAS) exploit this data to improve the genotyping resolution and 
make inferences about untyped SNPs [11]. This chapter proposes a similar technique for 
HIV-1 sequences. We incorporated more than seven hundred HIV-1 sequences from the 
NCBI repository into a linkage map that demonstrates co-evolving regions. 
Methods 
Data Sources 
We collected all whole genome HIV-1 viral sequences from the NCBI Genbank as of 
3/11/2010 [205]. This set comprised 1157 clade-B sequences. Since the Genbank 
 translation fields are inconsistently named, missing entirely or in some cases outright 
wrong, we employed our own translation tool. 
We created a local blast database using the ―canonical‖ sequences that are used in 
NCBI‘s HIV-1 Genotyping tool [206]. We then used BLASTx [60] to translate the query 
genomes and obtain the amino acid sequences for each protein. We used a restrictive 
filter and required that all proteins of the genome be present in the BLASTx query results 
with E-values < 0.01. This reduced our genome set to 732 HIV-1 genomes. We 
automated this using a custom MATLAB 2009b function and the Parallel Toolbox [207]. 
We developed a specialized program to find the LTR regions of each genome. We used a 
simple string-matching algorithm that attempts to find the longest window at the 3‘ and 
5‘ ends that match, with only one mismatch allowed. By allowing for a single mismatch, 
we found larger LTRs that would have been masked by rare sequencing errors. 
Mutual Information Calculations 
In order to determine the linkage between two regions of HIV, independent of functional 
sites, we employed a measure of mutual information as used in many bioinformatics 
techniques [208, 209] and shown in Equation 1. 
 
Equation 1: I(X,Y) the mutual information between a group of consecutive columns (X) and another 
group of consecutive columns (Y) in a sequence alignment. 
Where X and Y are groups of consecutive columns in the multiple alignments of two 
proteins while xi and yi are individual sequence instances in the respective columns. 
While p(xi), p(yi) and p(xi|yi) represent the likelihood of each observation in X, Y and X 
 given Y, respectively. This calculation provides a measure of how often any two amino-
acid windows are observed in the same genome. The value of I(X,Y) is always positive, a 
value of zero indicates no mutual information. In order to determine the statistical 
significance of any I(X,Y) we used a randomization technique. We shuffled the orders of 
the rows in each X and Y column and recalculated I(X,Y), termed I(Xr,Yr). In the shuffled 
cases, the mutual information should be low since the correlation is broken by the 
shuffling. We estimated the p-value of any I(X,Y) as the fraction of I(Xr,Yr) that are 
greater than the true I(X,Y), for this study we performed 5000 randomizations. This code 
was based on the Information Theory Toolbox for MATLAB [210]. We heavily modified 
it to improve vectorization, parallelization, speed and support for multicolumn and text 
data. 
We used an exhaustive search to examine every possible pair of locations to place 
windows of lengths ranging from 10 to 25. We then used a gradient descent optimization 
algorithm that expanded or shifted the regions until it found the maximum mutual 
information. We performed the p-value estimation independently for each window pair. 
However, since we are testing billions of possible pairs even a stringent p-value will 
allow a large number of false-positives. To account for this we employed a multiple-
testing correction procedure. We used MATLAB‘s mafdr function to calculate the 
expected number of falsely detected pairs [211]. We accepted all pairs that had an FDF < 
1.0 for later analysis; this resulted in a set of nearly 15,000 linked pairs of windows. 
Prediction Calculations 
Since mutual information only gives a measure of linkage but not predictive potential we 
calculated the prediction potential, Pr(Y|X). This value indicates the probability of 
 correctly determining the sequence of region Y given only the sequence of region X. This 
scheme allows multiple sequences (xi) can map to the same yi. We used a depth-first 
search method to find the optimal matching between all xi and yi. This is algorithmically 
shown in Code Block 1 and visually in Figure 21. Using this algorithm an invariant 
region can be perfectly predicted by any other region.  Since this is not biologically 
meaningful, we only considered regions that had lower than 80% conservation. 
 
 
Figure 21: A diagram of the prediction algorithm. Each color indicates a unique sequence instance.  
The letters marked in red are miss-predicted segments. 
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function L_val = CalculateLinkage(source, target) 
  
%Convert Columns to unique numbers 
[~, ~, source_inds] = unique(source, 'rows', 'first'); 
[~, ~, target_inds] = unique(target, 'rows', 'first'); 
  
RightCounts = 0; 
while ~isempty(source_inds) 
    %Count up all pairs 
    counts = accumarray([source_inds, target_inds], 1, ... 
        [max(sinds), max(tinds)]); 
     
    %Find the largest matched pair. 
    [val, ind] = max(counts(:)); 
    [srow, tcol]= ind2sub(size(counts), ind); 
     
    %Count up the corectly identified values 
    RightCounts = RightCounts+val; 
     
    %Delete all indices that are accounted for. 
    target_inds(source_inds == srow) = []; 
    source_inds(source_inds == srow) = []; 
end 
  
L_val = RightCounts/size(source,1); 
 
Code Block 1: The algorithmic implementation for 
calculating the Pr(Y|X). 
 Results 
Our results indicate a high level of both inter- and intra-protein linkage. Figure 23 shows 
a Circos graph indicating the regions of perfect predictive ability (Pr = 1.0) [212]. The 
abundance of links in the Figure 23(top), displaying perfect links originating from Env, 
can be partially accounted for by the overlapping genomics locations of Env, Rev, Nef 
and Vpu.  In an ideal situation, proteins with an overlapping genomic location would have 
complete prediction ability since they are copied from identical blueprints. However, due 
to occasional sequencing errors and the degenerate translation code, a missing nucleotide 
can have varying effects on each reading frame; this is demonstrated in Figure 24. 
 
Figure 22: A description of the translation of a nucleotide sequence with sequencing errors in red. In 
Frame 1, the sequencing error does not affect the translation because of the degeneracy of the codon 
translation table. However, in all other frames the error causes a break in the translation. 
Env has a highly complex 3D structure with multiple pockets, loops, beta-sheets and 
functional regions [213]. A complex 3D structure requires conserved regions across the 
entire amino acid length to preserve its integrity [213] and as such has high levels of 
intra-protein linkage. This is shown by the abundance of Env-Env links (green curves) in 
Figure 23(top) and Figure 24 with a set of example linkages in Table 5. Rev and Tat on 
the other hand have low levels of intra-protein linkage and correspondingly have simple 
3D structures [214, 215]. 
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Figure 23: Linkage map showing predicting regions of Env (top), Pol (middle) and Tat (bottom) 
connected through curved lines to the corresponding predicted regions of the HIV-1 genome. Only Pr 
= 1 lines are shown. The links are colored relative to the target predicted regions. The Env protein is 
in turquoise, Gag in light blue, Nef in blue, Pol in purple, Rev in red, Tat in black, Vif in grey and Vpr 
in green. 
  
Figure 24: The linkage map for the HIV-1 genome. The x-axis is the predicting region (X) and the y-axis is the predicted region (Y). The value at each 
location is Pr(Y|X). Only regions >90% are shown.   
 Table 5: A selection of perfect prediction potential matches between Env and other proteins. The first 
row in each grouping is the predictor and the second is the target. Only the two most frequent 
sequences are shown here.  The differences between each sequence are highlighted. 
 
Gene Start End Sequence Freq # Sequence Freq #
Env 9 12 MRV[-M] 61 2 MKVR 4 1
Env 104 116 SDAKAYDTEVHNV 250 1 SDAKAYETEVHNV 25 1
Env 92 105 VWKEA[PT]TTLFCA[AS]D 332 4 VWREANTTLFCASD 26 1
Pol 89 103 QVWGRD---N-N-SL 332 1 QVWGRD---N-N-SP 26 1
Env 92 105 VWKEA[PT]TTLFCA[AS]D 332 4 VWREANTTLFCASD 26 1
Env 506 520 SFNCGGEFFYCNSTQ 332 1 TFNCGGEFFYCNSTQ 26 1
Env 105 119 [DN]AKAYDTEVHNVWAT 254 2 DA[KR]AYDTEAHNVWAT 42 2
Rev 66 78 PLERLTLDCNEDC 254 1 PLERLTLDCDEDC 42 1
Env 105 117 DAKAYDT[EK][AV]HNVW 290 4 DAKAYETEVHNVW 25 1
Env 990 1003 ELKNSAVSLLNATA 290 1 ELRNSAVSLLNATA 25 1
Env 118 134 ATHACVPTDPNPQEVV[LM] 207 2 ATHACVPTDPNPQEVLL 25 1
Vpu 66 78 SAL--------VE 207 1 SAL--------VD 25 1
Env 144 157 MWKNNMV[DE]QMHEDI 276 2 MWKNDMVDQMHED[IV] 12 2
Env 873 886 VGLRIVFAVLSIVN 276 1 VGLRIVFSVLSIVN 12 1
Env 154 166 H[EK]DIISLWDQSLK 352 2 HEDII[GS]LWDESLK 25 2
Rev 67 79 LERLTLDCNEDCG 352 1 LERLTLDCSEDCG 120 1
Env 300 312 ITQACPK[AV][ST]FEPI 331 4 VTQACPKVSFQPI 6 1
Pol 40 56 ---E-QTRAN----SP- 331 1 -----QTRAN----SP- 19 1
Env 300 312 ITQACPKVSFEPI 285 1 VTQACPKVSFQPI 6 1
Env 508 523 NCGGEFFYCNSTQLF- 285 1 NCGGEFFYCDTKQLF- 7 1
Env 312 325 IPIHY[CX]APAGF[AT]IL 332 4 IPIHYC[AT]PAGYAIL 21 2
Gag 467 479 T-E-RQ-ANFLGK 353 1 T-E-RQ-ANFLGK 353 1
  
Table 6: Clinically relevant mutations in numerous HIV-1 proteins. The linked regions have >90% 
prediction potential (Pr > 0.9) for the mutation region. 
Gene Region Description Linked Regions Reference 
Vpr 70-94 Increased Apoptosis Env 222-234, Env 
556-572, Tat 63-77 
[216] 
Nef 138-150 Vaccine Escape Env 611-624 [217] 
Gag-capsid 358-370 Increased resistance to 
BVM 
Env 196-208, Env 
248-272, Env 611-
624, Env 820-832, 
Env 924-936, Vif 28-
41, Rev 43-59 
[218] 
Env-gp41 33-40 Increased resistance to 
entry inhibitors 
Env 444-456, Env 
601-620 
[219] 
Pol-integrase 140-150 Increased resistance to 
integrase inhibitors 
Env 234-247, Env 
443-455, Env 611-624 
[220] 
Table 7: A table of the fraction of each gene that is predicted by the Env 550-630 region. Each 
column represents a different Pr(Y|X) cutoff.   
 
Gene 70% 80% 90%
Env 91.2% 73.9% 38.1%
Gag 90.0% 81.9% 39.9%
Nef 83.2% 50.9% 0.9%
Pol 89.8% 84.0% 55.1%
Rev 69.7% 58.2% 10.7%
Tat 89.7% 73.1% 16.7%
Vif 77.1% 77.1% 31.8%
Vpr 84.2% 71.3% 25.7%
Vpu 71.4% 58.2% 29.7%
LTR 92.8% 78.1% 53.8%
All 88.7% 76.5% 41.7%
 Discussion 
Our study provides an insight into the evolutionary path of HIV-1 mutations. HIV-1 
mutations are restricted by the functional activities of specific viral proteins, interactions 
with host proteins, interactions with viral proteins and the need for immune and 
therapeutic escape. By analyzing a large corpus of more than seven hundred whole 
genome sequences, we have been able to find statistically significant linkages between 
many regions of the HIV-1 genome. 
We foresee two main applications of the viral linkage map we have proposed, the first of 
which is finding binding sites between HIV-1 proteins. The interaction and cooperation 
between HIV-1 proteins is poorly understood. This linkage map provides a list of 
potential binding sites since a mutation in one region would require a compensatory 
mutation in the binding partner.  Due to the current lack of known binding regions, we 
cannot reliably confirm this hypothesis. 
The second application is to predict the sequence of the HIV-1 genome outside of the 
normally sequenced regions. Table 6 is a small collection of clinically relevant mutations 
in various HIV-1 proteins. It includes mutations in Nef that facilitate vaccine escape, Vpr 
mutations that increase apoptosis and mutations in Env and Pol that confer resistance to 
antiviral therapies. Sequencing all of these regions would require five separate 
sequencing reactions for each patient. However, the viral linkage map shows that 
sequencing the Env 550-630 region would provide >90% for all of these mutations. This 
region actually predicts 41% of the genome at >90% accuracy and is shown Table 7. 
 Conclusions 
To our knowledge, this is the first attempt to perform a genome linkage analysis of HIV-
1. We have shown that mutations along the HIV-1 genome that increase viral fitness, 
escape immune pressure, or resist therapeutic intervention are linked to each other. We 
show a way to exploit this linkage by sequencing a small region of the HIV-1 genome to 
gain information about the rest of the genome. Our research shows that sequencing the 
Env gene provides information about virtually every other region of the viral genome. 
For example, the Env 550-630 can predict 60% of the entire genome at greater than 90% 
accuracy. The biological significance for this is still unclear. Are they binding events? 
Are they regulatory? Is a mutation in Env causing mutations across the genome? Are 
mutations across the genome causing Env to change? This dataset is insufficient to 
elucidate these questions. The causal direction of the mutations could only be 
investigated through longitudinal studies of individuals or cell-line data. The time-course 
of these mutations would shed light on the biological significance of these linked 
windows. 
While we present the idea that these mutations are linked, perhaps due to binding 
interactions or selective pressure, this is not the only plausible explanation. It is possible 
that this method is highlighting the differences between various subClades of Subtype B 
sequences present in our dataset. Further work is needed to distinguish the possible 
avenues of linkage across the HIV-1 genome. In our future work, we plan to use 
permutation studies to distinguish between these alternative hypotheses. 
 Chapter 5: Conclusions 
This unifying thread through these three projects is the use of publically available data for 
the prediction across diverse topics related to host-pathogen crosstalk. Human and 
pathogen binding data coupled with ODE models predicted the time-course of H. pylori 
infection that is confirmed by microarray analysis. HIV-1 viral sequence data merged 
with human sequence motifs predicted the progression of anti-viral therapy. Lastly, a 
large collection of whole genome HIV-1 sequence has shown that fragments of the viral 
genome can predict the sequence of other regions. These topics cover a large breadth of 
the areas of bioinformatics. 
The host-pathogen research has shown that it is possible to predict the time-course of a 
pathogenic infection using only mathematical concepts such as Michaelis-Menten 
equations and binding constants. Genome-scale, transcriptomic techniques confirmed the 
granular time-course of the H. pylori infection. This technique could be applied to other 
bacterial and viral pathogens that have a small number of interactions with their hosts. 
The limiting factor in this technique is the time it takes to build the ODE models of both 
the pathogen and human pathways. 
The technique employed in the H. pylori project took advantage of previous work that 
already defined the MAP Kinase and Apoptosis pathways and a small number of 
interactions with pathogenic proteins. In the case of HIV-1, this would be an intractable 
problem. There are thousands of known interactions [47, 65, 221-224] with little 
information on binding parameters. HIV-1 interactions also span beyond the MAP Kinase 
and Apoptosis pathways. While a similar ODE model of HIV-1 infection is not an 
 impossible task, our current knowledge would leave the majority of binding parameters 
unknown. 
Since our current knowledge of HIV-1 binding parameters prevented the application of 
ODE modeling, this thesis proposes a technique that does not require such information. 
This technique takes advantage solely of the knowledge of HIV-1 binding partners. Since 
HIV-1 binding occurs at host sequence motifs [65, 225] their expression should have an 
impact on therapeutic progression. This bypasses the biology by using an engineering 
approach that treats the entire system (HIV-1 pathology, host biology, therapeutic action, 
etc.) as a black box and creates a prediction algorithm that maps inputs (motifs) to the 
output (responder status). Some information about the biology is gleaned from this 
technique but that is only a by-product of the prediction method. 
In this method, the lack of biological intuition comes from the nature of the input data. 
Motifs on the reverse transcriptase and protease of HIV-1 infer the potential binding 
partners of these proteins. They do not inherently predict the binding and efficacy of 
antiretroviral drugs. In some instances, the sequence motifs overlap the known drug 
binding sites implying that the loss of one correlates with a loss of the other but this 
situation only occurs in only a handful of cases. The effect of a loss or gain of a sequence 
motif on these proteins likely reflects a change in the viral fitness in various aspects of 
the pathology. The increased effect of various drug interventions reflects how well they 
stress the virus in these aspects. 
The thousands of interactions of HIV-1 with human proteins are only partially accounted 
for by the common regions of clinical sequencing: PR, RT and occasionally Env. The 
viral linkage map was constructed to fill this gap. The map shows that despite the 
 common conception that the viral genome mutates rapidly and randomly is only partially 
true. A mutation in one area will often correlate with a mutation on another gene. This 
may be due to binding events, regulatory interactions, or compensatory activity related to 
downstream interactions. 
The linkage map shows that the HIV-1 Env has a large predictive ability across the entire 
genome, for example, the Env 550-630 can predict 40% of the entire genome at greater 
than 90% accuracy. The biological significance for this is still unclear. Are they binding 
events or other regulatory changes? Our current understanding of the interactions 
between HIV-1 proteins makes this a difficult question to answer. However, armed with 
this linkage data wet-lab researchers could begin to untangle the web of interactions from 
directions in this map. 
The three techniques explored in this thesis for decoding the host-pathogen crosstalk both 
form and generate hypotheses. The technique used in investigating H. pylori infections 
confirmed that binding events are sufficient for sustained infection and generated 
hypotheses about transcription factor activity. The study of HIV infection confirmed that 
it is possible to predict therapeutic progression while generating hypotheses about the 
nature of the network of possible interactions between human proteins and HIV PR and 
RT. The viral linkage map may help researchers analyze HIV-1 on a genome scale. Taken 
together, these techniques form a systems biology approach to host-pathogens 
interactions for future researchers to apply to new and various diseases. 
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